Definition: In this task, you're given a paragraph from the research paper and your task is to generate a suitable title for the research paper based on the given paper. Under 100 words is a good title length.
Input: The original scientifi c strategy behind vaccinology has historically been to "isolate, inactivate, and inject," fi rst invoked by Louis Pasteur. The recombinant DNA and nanotechnology did much enlarge the repertoire on vaccines, which is today based on three adjusted principles, attenuation, inactivation, and recombination, as shown in Fig. 9 .1 . The three principles are regarded as equal, and all experimental possibilities for a new vaccine development against a pathogen should be studied in detail. The recombinant DNA and nanotechnology did not change the basic scientifi c strategy: live and non-live vaccines. Live vaccines are non-adjuvanted, and non-live vaccines are generally adjuvanted. New developments against tuberculosis (TB) highlight this broad experimental approach: Today, it estimated that about one-third of the world population is infected with the TB bacillus. Approximately 54 million people are infected every year, 9.4 million develop the disease, and 1.7 million die from this curable disease. The TB bacillus kills more people than any other infectious agent alone. Currently, BCG (Bacillus Calmette-Guérin) is the only vaccine recommended by the WHO, with more than three billion doses administered since its introduction in 1921. BCG is prepared from a strain of the attenuated live bovine tuberculosis bacillus, Mycobacterium bovis , which lost its virulence in humans by being specially subcultured in an artifi cial medium. However, although it protects newborns and children from severe forms of TB, its effi cacy against pulmonary TB in adolescents and adults is far from optimal, with protection rates varying between 0 and 80 % according to the geographical area. Contents Live and Non-live Vaccines

Types of Recombinant Vaccines 9.1 Live and Non-live Vaccines